Company adds Women's Hospital to Growing List of New Breast Product Clients
BOSTON, Oct. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's Mammo View(TM) System and other surgical products have been purchased and are now in use at the Women's Hospital of Baton Rouge, LA. Solos Endoscopy's Mammo View (TM) system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise.
The Women's Hospital is a 225-bed, private, not-for-profit organization and is one of the largest women's specialty hospitals in the United States. The Women's Hospital is recognized throughout the country for its innovative programs for women and their families. Each of the Women's Hospital services is designed to accommodate the specific needs of women and infants.
"We cannot be happier to introduce our Mammo View(TM) System into a hospital with specific services geared to the health and care of women. We are pleased that we were able to place our products into one of the most recognized women's hospital in this country," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2008 PR Newswire.
All rights reserved